Published 11 days ago

World's first jab to stop skin cancer being tested in UK patients

A personalized mRNA cancer jab is being tested in British patients for melanoma, with potential to target bladder, lung, and kidney cancer.
In a trial, the jab reduced the risk of cancer recurrence in melanoma patients, leading to a final trial launch.
The therapy involves DNA sequencing of a tumor sample and artificial intelligence, showing promising results for high-risk melanoma patients.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

BBC News

British man tests first personalised melanoma vaccine

Steve Young is part of the tests to see if an mRNA jab can stop the deadliest skin cancer returning.

11 days ago·United Kingdom

Read Full Article

The Guardian

‘Real hope’ for cancer cure as personal mRNA vaccine for melanoma trialled

Excitement among patients and researchers as custom-built jabs enter phase 3 trial

11 days ago·London, United Kingdom

Read Full Article

The Independent

British patients test world’s first personalised mRNA jab for melanoma

Moderna and MSD are researching how their therapy could treat a wide range of cancers.

11 days ago·London, United Kingdom

Read Full Article

Daily Express

Cancer breakthrough as scientists develop jab that could provide miracle cure

Now in global studies, the jab may also be effective against lung, bladder and kidney cancer.

11 days ago·United Kingdom

Read Full Article

Daily Mirror

Groundbreaking cancer vaccine trialled on British cancer patients in world first

The groundbreaking jab could stop the cancer from returning in patients who have already been diagnosed in the UK

11 days ago·London, United Kingdom

Read Full Article

Shropshire Star

British patients test world’s first personalised mRNA jab for melanoma

The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in British patients.

11 days ago·Ketley, United Kingdom

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year